New chemotherapy for older adults with high-risk AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new form of chemotherapy (liposomal cytarabine-daunorubicin) for older adults with high-risk AML that has not been treated yet. It is designed for people whose AML is secondary to a previous cancer treatment or blood disorder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old.
- Your AML is high-risk, such as AML that came after another cancer treatment (therapy-related), after a prior blood disorder (MDS or CMML), or has certain chromosome changes.
- You are generally able to care for yourself (ECOG score 0-2).
- Your heart, kidney, and liver function are within acceptable limits.
- You have not had prior treatment for AML (except for hydroxyurea).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
This trial tests a combination of two chemotherapy regimens given in turns for people with newly diagnosed acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The goal is to find a gentler but effective treatment option.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Hear when a new High-risk (Secondary) Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.